13F Holdings
中文EN

NXL Nexalin Technology, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1527352 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY76.7%
TTM net income YoY-8.0%
TTM EPS YoY108.1%
Revenue 3-yr CAGR29.2%
Net income 3-yr CAGR—

Margins

Gross margin82.4%
Operating margin-3,386.0%
Net margin-3,380.6%
FCF margin—
EBITDA margin—

Returns

ROE-372.6%
ROA-222.9%
ROIC (approx.)-406.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets92.0%
Debt / equity0.00x
Current ratio0.69x
Interest coverage-179.02x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-74.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$301,647$168,721$110,748$1.32M$144,065
Cost of revenue$61,373$36,593$25,688$363,212$21,442
Gross profit$240,274$132,128$85,060$958,145$122,623
R&D expense$1.08M$1.19M$1.92M$511,000$139,000
SG&A expense$4.40M$4.23M$1.90M$1.49M$5.22M
Operating income-$8.39M-$7.75M-$5.70M-$1.83M-$6.02M
Interest expense-$8,240-$3,193$38,835$59,382$82,319
Pretax income-$8.22M-$7.61M-$4.65M——
Net income-$8.22M-$7.61M-$4.65M-$1.70M-$6.08M
EBITDA——-$5.70M-$1.83M-$6.02M
EPS (basic)-0.50-0.83-0.63-0.30—
EPS (diluted)-0.50-0.83-0.63-0.30—
Weighted avg. shares (diluted)16.39M9.22M7.36M5.57M—
Banking
Net interest income-$8,240-$3,193$38,835——
Balance sheet
Cash & equivalents$654,783$574,485$580,230$162,743$661,778
Short-term investments$3.07M$2.91M$2.37M$6.83M—
Receivables$81,571$13,043$9,369$4,875$16,303
Inventory$131,473$174,578$156,420$154,370$31,410
Current assets$4.30M$3.96M$3.43M$7.43M$752,659
PP&E, net———$503$1,039
Intangibles$336,049$260,727$105,528——
Total assets$4.64M$4.22M$3.63M$7.43M$753,698
Current liabilities$887,333$546,694$425,281$1.95M$2.36M
Total liabilities$887,333$546,694$425,281$1.95M$2.44M
Shareholders' equity$3.75M$3.68M$3.21M$5.48M-$1.68M
Shares outstanding639,54413.30M7.44M7.29M4.88M
Cash flow statement
Operating cash flow-$4.96M-$3.94M-$3.84M-$2.22M-$1.08M
Investing cash flow-$131,991-$577,539$4.45M-$6.79M—
Financing cash flow$5.17M$4.52M-$200,000$8.51M$1.66M
Depreciation & amortization——$503$535$537
Stock-based compensation$3.12M$3.56M$2.41M$270,670$4.48M

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.